Pharma and biotech companies, led by Eli Lilly, Biogen, and Crispr, are poised for huge gains as the new year begins, propelled by multibillion-dollar mergers, positive trial outcomes, and cutting-edge medical advances such as CRISPR gene-editing entering the mainstream.
The promise of a bright 2024 comes after about two years of mediocrity. The likely impact of impending Medicare drug pricing talks has weighed on biopharma companies. Big Pharma is also prepping for a patent cliff, which is predicted to shake the industry later this decade.
Analysts say there are now reasons to be positive.
Tema ETFs investment partner David Song is “cautiously optimistic” about the macro issues affecting biotech companies in 2024. According to Kyle Rasbach, manager of Eventide Asset Management’s Healthcare & Life Sciences fund, “we are closer than ever to a more amenable environment for biotech
Tema ETFs investment partner David Song is “cautiously optimistic” about the macro issues affecting biotech companies in 2024. According to Kyle Rasbach, manager of Eventide Asset Management’s Healthcare & Life Sciences fund, “we are closer than ever to a more amenable environment for biotech. The tide is turning, according to Arrowhead Pharmaceuticals (ARWR) CEO Christopher Anzalone.
